Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.

CONCLUSIONS: Vadadustat increased Hb levels and improved biomarkers of iron mobilization and utilization in patients with anemia secondary to stage 3 or 4 CKD. Global multicenter, randomized phase 3 trials are ongoing in non-dialysis-dependent and dialysis-dependent patients. PMID: 28343225 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28343225?dopt=Abstract

Source: American Journal of Nephrology - March 25, 2017 Category: Urology & Nephrology Authors: Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM Tags: Am J Nephrol Source Type: research